→ The FDA has approved an IV version of the already OK’d drug Varubi, used to treat the nausea and vomiting triggered by chemotherapy. “The majority of NK-1 receptor antagonist doses are administered intravenously in the U.S., and with the introduction of Varubi IV, we now offer healthcare providers a unique, easy-to-use option that fits well into standard operating practices of a chemotherapy clinic or hospital,” said Tesaro president Mary Lynne Hedley.
→ Evotec AG and Tesaro launched a three-year discovery deal to track down and develop novel small molecule product candidates against an undisclosed immuno-oncology target.
→ The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has offered GSK a key endorsement for their new shingles vaccine Shingrix. A slight majority backed Shingrix over Merck’s long established rival Zostavax, which is expected to give up a big share of the market now.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription